ArticleLaboratory animal research2026
Evaluation of a human slow-release buprenorphine formulation in rats - tactile sensitivity and plasma concentration.
Article in Laboratory animal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundOpioids are considered ideal for managing moderate to severe post-operative pain in laboratory rodents, with buprenorphine being one of the most commonly used analgesics in rats. A long-acting buprenorphine formulation would be highly beneficial to avoid frequent dosing of postoperative animals; however, buprenorphine depot formulations developed for animal use are not available in Europe. The purpose of the present study was therefore to evaluate the effects in rats of a long-acting subcutaneous depot injection with buprenorphine developed for humans (Buvidal).
resultsBuvidal was evaluated in male Sprague Dawley rats alongside conventional short-acting buprenorphine (Temgesic) delivered subcutaneously and orally, a non-opioid analgesic (carprofen), and controls (saline). All three buprenorphine formulations resulted in significantly reduced mechanical sensitivity when assessed in pain-free, naïve rats using the von Frey pressure test at early time points (3-6 h), whereas carprofen and saline had no effect on tactile sensitivity. In a hypersensitivity model of cephalic allodynia, the hypoalgesic effect of Buvidal lasted beyond 24 h. Plasma concentrations support prolonged drug exposure following administration of the long-acting formulation, and levels exceeding 1 ng/mL were observed during periods of reduced tactile sensitivity. No significant effect on locomotor activity was found in an open field test following buprenorphine administration. Transient pica-like chewing behaviour and reduced alertness were observed in some buprenorphine-treated animals during the first hours after drug administration.
conclusionsThe human slow-release buprenorphine formulation Buvidal produced sustained systemic exposure and prolonged hypoalgesic effects in male rats, as demonstrated in the cephalic hypersensitivity model, consistent with depot release kinetics. These results show that Buvidal is pharmacologically active in rats and may represent a potential approach for achieving sustained buprenorphine effects in experimental studies requiring prolonged opioid analgesia where rodent-specific formulations are unavailable, although further evaluation of safety, dosing, and generalizability is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.